Michael Powell

San Francisco Bay Area United States

Chief Scientific Officer at DiaCarta, Inc,

Medical / Health Care / Pharmaceuticals

The study of genetic variations (mutations) is currently undergoing a revolution in the field of targeted therapeutics; especially for the treatment of cancer. DiaCarta has innovative technologies that allow the rapid detection of known genetic variations that affect a patients response to drugs. DiaCarta's Molecular test kits are aimed at supporting the continuing growth in personalized therapies for cancer. DiaCarta has a suite of Somatic Mutation tests including KRAS, NRAS, BRAF, EGFR, ALK, JAK2, PIK3CA, c-KIT and PDGFR that cover all of the important genetic variations important in targeted therapy.